Effects of mefloquine alone and with alcohol on psychomotor and driving performance

European Journal of Clinical Pharmacology

Volumn 50, Issue 6, 1996, Pages 475-482

  Vuurman, E F P M ^a   Muntjewerff, N D ^a   Uiterwijk, M M C ^a   Van Veggel, L M A ^a   Crevoisier, C ^b   Haglund, L ^b   Kinzig, M ^c   O'Hanlon, J F ^a  

^a MAASTRICHT UNIVERSITY   (Netherlands)

^b F HOFFMANN LA ROCHE LTD   (Switzerland)

^c Institute for Biomedical and Pharmaceutical Research   (Germany)

Author keywords

Alcohol interactions; Antimalarial drugs; Driving performance; Mefloquine; SDLP

Indexed keywords

ALCOHOL; MEFLOQUINE; PLACEBO;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOUBLE BLIND PROCEDURE; DRIVING ABILITY; FATIGUE; FEMALE; HEADACHE; HUMAN; HUMAN EXPERIMENT; MALE; NAUSEA; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; VERTIGO;

ADULT; ANTIMALARIALS; CENTRAL NERVOUS SYSTEM DEPRESSANTS; DOUBLE-BLIND METHOD; DRUG INTERACTIONS; ETHANOL; FEMALE; HUMANS; MALE; MEFLOQUINE; MIDDLE AGED; PSYCHOMOTOR PERFORMANCE;

EID: 0029783814     PISSN: 00316970     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002280050144     Document Type: Article

References (16)

1. Bem JL, Kerr L, Stuerchler D (1992) Mefloquine prophylaxis: an overview of spontaneous reports of severe psychiatric reactions and convulsions. J Trop Med Hygiene 95: 167-179
2. Boudreau E, Schuster B, Sanchez J, Novakowski W, Johnson R, Redmond D, Hanson R, Dausel L (1993) Tolerability of prophylactic Lariam regimens. Trop Med Parasitol 44:251-265
3. Engel GL, Romano J, Ferris EB (1947) Effect of quinacrine (Atabrine) on the central nervous system. Arch Neurol 58: 337-350
4. Dixon WJ (1988) BMDP Statistical Software Manual Vol 1. University of California Press, Berkley
5. Jex HR, McDonnel JD, Phatak AV (1966) Critical tracking task for manual control research. IEEE Trans Hum Fac Eng HFE-7:138-147
6. Kapteyn TS, Bles W, Njiokiktjein ChJ, Kodde L, Massen Ch. Mol JMF (1983) Standardization in platform stabilometry being part of posturography. Agressol 24:321-326
7. Kinzig MF, Sörgel F (1995) LC-MS/MS. Procedures using multiple reaction monitoring (MRM) for the determination of mefloquine and its metabolite in human plasma. GTF-Gesellschaft für Therapeutische Forschung mbH (Nürnberg-Heroldsberg, Germany). Validation Report MEF- VAL-294P 95
8. McClelland GR (1989) Body Sway and the effects of psychoactive drugs - A review. Hum Psychopharmacol 4:3-14
9. Mimica J, Fry W, Eckert G, Schwartz DE (1983) Multiple-dose kinetic study of mefloquine in healthy male volunteers. Chemother 29: 184-187
10. O'Hanlon JF (1984) Driving performance under the influence of drugs: rationale for and application of a new test. Br J Clin Pharmacol 18: 121S-129S
11. O'Hanlon JF, Volkerts ER (1988) Driving performance decrement following medicinal drugs. In: Leonard JP (ed) Vigilance: methods, models and regulation. Peter Lang, Frankfurt am Main, pp 99-110
12. Pennie RA, Koren G, Crevoisier C (1993) Steady state pharmacokinetics of mefloquine in long-term travellers. Trans Roy Soc Trop Med 87:459-463
13. Ramaekers JG, O'Hanlon JF (1994) Acrivastine terfenadine and diphenhydramine effects on driving performance as a function of dose and time after dosing. Eur J Clin Pharmacol 47: 261-266
14. Vuurman EFPM, Uiterwijk MMC, Rosenzweig P, O'Hanlon JF (1994) Effects of mizolastine and elemastine on actual driving and psychomotor performance in healthy volunteers. Eur J Clin Pharmacol 47:253-259
15. Wallace DJ (1994) Antimalarial agents and lupus. Rheum Dis Clinics North Am 20:243-263
16. Wittes RC, Saginur R (1995) Adverse reactions to mefloquine associated with ethanol ingestion. Can Med Assoc J 152: 515-517